BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:02 PM
 | 
Jul 29, 2009
 |  BC Extra  |  Top Story

Ofatumumab meets RA endpoint

Genmab A/S (CSE:GEN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said top-line data showed that IV ofatumumab met the primary endpoint of significantly improving...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >